Connect with us

Business

CSL (ASX:CSL) share price falls amid ongoing AstraZeneca uncertainty

Published

on

CSL Limited (ASX: CSL) shares are edging lower today as ongoing uncertainty over the side effects of the AstraZeneca COVID-19 vaccine continues. At the time of writing, the CSL share price is trading 0.11% lower at $265.22.

CSL is involved in the research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. The company advised late last month it is set to produce more than 1 million doses of the AstraZeneca vaccine per week. 

It was commissioned by the government to produce 50 million doses of the AstraZeneca vaccine, before the vaccine was found to create a one-in-200,000 chance of blood clots – termed thrombosis with thrombocytopenia – around the brain and abdomen.

This led to the…



Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

2 fantastic ASX 50 shares that could be in the buy zone
Why does the Mesoblast (ASX:MSB) share price keep falling?